Homrich & Berg Has $1.47 Million Holdings in Merck & Co. (MRK)

Homrich & Berg lessened its stake in Merck & Co. (NYSE:MRK) by 4.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 26,035 shares of the company’s stock after selling 1,191 shares during the period. Homrich & Berg’s holdings in Merck & Co. were worth $1,465,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in MRK. Honeywell International Inc. lifted its stake in shares of Merck & Co. by 18.8% in the 3rd quarter. Honeywell International Inc. now owns 633,700 shares of the company’s stock valued at $40,576,000 after purchasing an additional 100,500 shares during the period. D.A. Davidson & CO. lifted its stake in shares of Merck & Co. by 18.3% in the 3rd quarter. D.A. Davidson & CO. now owns 524,481 shares of the company’s stock valued at $33,582,000 after purchasing an additional 81,290 shares during the period. Train Babcock Advisors LLC lifted its stake in shares of Merck & Co. by 19.8% in the 4th quarter. Train Babcock Advisors LLC now owns 10,810 shares of the company’s stock valued at $609,000 after purchasing an additional 1,785 shares during the period. Ascension Asset Management LLC acquired a new position in shares of Merck & Co. in the 4th quarter valued at about $644,000. Finally, Mork Capital Management LLC acquired a new position in shares of Merck & Co. in the 4th quarter valued at about $990,000. Hedge funds and other institutional investors own 74.63% of the company’s stock.

How to Become a New Pot Stock Millionaire

MRK stock opened at $57.17 on Monday. Merck & Co. has a fifty-two week low of $52.83 and a fifty-two week high of $66.41. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.06 and a current ratio of 1.33. The company has a market cap of $152,981.83, a P/E ratio of 14.36, a PEG ratio of 2.39 and a beta of 0.78.

Merck & Co. (NYSE:MRK) last posted its quarterly earnings results on Friday, February 2nd. The company reported $0.98 earnings per share for the quarter, topping analysts’ consensus estimates of $0.94 by $0.04. Merck & Co. had a return on equity of 28.61% and a net margin of 6.40%. The business had revenue of $10.43 billion for the quarter, compared to the consensus estimate of $10.48 billion. During the same period in the prior year, the business earned $0.89 EPS. The firm’s revenue for the quarter was up 3.1% on a year-over-year basis. equities research analysts forecast that Merck & Co. will post 4.16 earnings per share for the current year.

The company also recently declared a quarterly dividend, which was paid on Friday, April 6th. Investors of record on Thursday, March 15th were paid a dividend of $0.48 per share. This represents a $1.92 dividend on an annualized basis and a yield of 3.36%. The ex-dividend date was Wednesday, March 14th. Merck & Co.’s dividend payout ratio (DPR) is currently 48.24%.

A number of research analysts have recently issued reports on MRK shares. ValuEngine raised Merck & Co. from a “hold” rating to a “buy” rating in a research note on Wednesday, January 10th. BMO Capital Markets set a $68.00 price objective on Merck & Co. and gave the company a “buy” rating in a research note on Tuesday, January 16th. SunTrust Banks raised Merck & Co. from a “hold” rating to a “buy” rating and boosted their price objective for the company from $54.00 to $72.00 in a research note on Tuesday, January 16th. Jefferies Group reissued a “hold” rating and issued a $55.00 price objective on shares of Merck & Co. in a research note on Tuesday, January 16th. Finally, Credit Suisse Group dropped their price objective on Merck & Co. from $67.00 to $66.00 and set an “outperform” rating on the stock in a research note on Monday, February 5th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and thirteen have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $66.53.

In related news, Director Wendell P. Weeks sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $53.57, for a total transaction of $267,850.00. Following the transaction, the director now directly owns 5,100 shares of the company’s stock, valued at approximately $273,207. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Weir Mirian M. Graddick sold 60,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $61.63, for a total value of $3,697,800.00. Following the transaction, the insider now directly owns 101,484 shares in the company, valued at $6,254,458.92. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 77,500 shares of company stock worth $4,736,025. 0.25% of the stock is owned by company insiders.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.chaffeybreeze.com/2018/04/16/homrich-berg-has-1-47-million-holdings-in-merck-co-mrk.html.

Merck & Co. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

Institutional Ownership by Quarter for Merck & Co. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply